AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19854614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl anesthesia
Number of subjects: 140
Study 19854614 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-fentanyl anesthesia
Number of subjects: 140
Study 19167595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 143
Study 19167595 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg/d
Number of subjects: 143
Study 15669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 302
Study 15669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 302
Study 15669897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 14700102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 32
Study 14700102 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%-lidocaine 2% mixture
Number of subjects: 32
Study 10562789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope
Number of subjects: 30
Study 10562789 — intervention group
Group type: COMPARATOR
Intervention: Conventional blind placement
Number of subjects: 30
Study 8685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 52
Study 8685930 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (150 mg/d)
Number of subjects: 52
Study 8685930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2060201 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 36
Study 2060201 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 36
Study 29658455 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention via fiber bronchoscope (≤3 days)
Number of subjects: 96
Study 29658455 — intervention group
Group type: COMPARATOR
Intervention: Late intervention via fiber bronchoscope (>3 days)
Number of subjects: 96
Study 26333596 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1116
Study 26333596 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1116
Study 25458650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar with clopidogrel
Number of subjects: 12887
Study 25458650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar without clopidogrel
Number of subjects: 12887
Study 22380768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric acupoint stimulation (TEAS) administered at bilateral P6 acupoint for 30 min after basal anesthesia
Number of subjects: 70
Study 22380768 — intervention group
Group type: COMPARATOR
Intervention: Control group (an electrode placed on the arm without stimulus)
Number of subjects: 70
Study 20113455 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonation water
Number of subjects: 0
Study 20113455 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonation water and leg exercise during donation
Number of subjects: 0
Study 20113455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (leg exercise before venipuncture)
Number of subjects: 0
Study 20113455 — intervention group
Group type: COMPARATOR
Intervention: Standard donation
Number of subjects: 0
Study 18220081 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg
Number of subjects: 1018
Study 18220081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 16820548 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice per day (n = 603)
Number of subjects: 1210
Study 16820548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 607)
Number of subjects: 1210
Study 14584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental mouth rinse A
Number of subjects: 0
Study 14584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental mouth rinse B
Number of subjects: 0
Study 14584721 — intervention group
Group type: COMPARATOR
Intervention: Control mouth rinse
Number of subjects: 0
Study 10983675 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 0
Study 10983675 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid medium
Number of subjects: 0
Study 9181646 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating treatment with zidovudine 600 mg/day and didanosine 400 mg/day
Number of subjects: 552
Study 9181646 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 600 mg/day
Number of subjects: 552
Study 9181646 — intervention group
Group type: COMPARATOR
Intervention: Didanosine 400 mg/day
Number of subjects: 552
Study 1322184 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard GVHD prophylaxis (methotrexate or cyclosporin A)
Number of subjects: 262
Study 1322184 — intervention group
Group type: COMPARATOR
Intervention: Intensified GVHD prophylaxis (methotrexate combined with cyclosporin A, in vivo anti-T-cell monoclonal antibodies, or various procedures to reduce T-cell numbers)
Number of subjects: 262
Study 12340958 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine + diazepam
Number of subjects: 60
Study 12340958 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl + thiopentone
Number of subjects: 60
Study 12340958 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane or enflurane
Number of subjects: 60
Study 12340958 — intervention group
Group type: EXPERIMENTAL
Intervention: enflurane
Number of subjects: 60
Study 31179618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle support services provided by pharmacists after 4 hours of training; Pharmacists provided guidance to 1-3 hypertension patients over 5 meetings.
Number of subjects: 50
Study 31179618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle support services provided by pharmacists after training; Pharmacists provided guidance to hypertension patients.
Number of subjects: 50
Study 30193294 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Administered Behavioral Treatment (GBT)
Number of subjects: 463
Study 30193294 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 463
Study 28073411 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells (hUCMSCs) via the proper hepatic artery or the portal vein, intravenous infusion of 4×10^8 hUCMSCs in two doses
Number of subjects: 65
Study 28073411 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 65
Study 24614911 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus metformin
Number of subjects: 99
Study 24614911 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride
Number of subjects: 99
Study 24614911 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride plus metformin
Number of subjects: 99
Study 21948812 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (penetrating 'deqi' creating acupuncture)
Number of subjects: 215
Study 21948812 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (non‐penetrating sham needles)
Number of subjects: 215
Study 20308357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 20308357 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 18609354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 18609354 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 808
Study 18609354 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor
Number of subjects: 808
Study 18609354 — intervention group
Group type: EXPERIMENTAL
Intervention: Study duration
Number of subjects: 808
Study 18609354 — intervention group
Group type: EXPERIMENTAL
Intervention: ANM skill level
Number of subjects: 808
Study 16209031 — intervention group
Group type: EXPERIMENTAL
Intervention: Various exposure variables analyzed in cases (children with diarrhoea)
Number of subjects: 1996
Study 16209031 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without diarrhoea)
Number of subjects: 1996
Study 11797183 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 13000
Study 10351191 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) therapy
Number of subjects: 177
Study 10351191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 8524201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinasek
Number of subjects: 40
Study 8524201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1983500 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2‐0.4 mg/kg/h)
Number of subjects: 52
Study 1983500 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidin (1‐2 mg/d)
Number of subjects: 52
Study 1983500 — intervention group
Group type: COMPARATOR
Intervention: Alcohol substitution (1‐2 g/kg/d)
Number of subjects: 52
Study 7396104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 3
Study 7396104 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 3
Study 7396104 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 3
Study 7396104 — intervention group
Group type: COMPARATOR
Intervention: Epidural and neuroleptanaesthesia
Number of subjects: 3
Study 30972746 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 663
Study 30972746 — intervention group
Group type: COMPARATOR
Intervention: ustekinumab 45 or 90 mg
Number of subjects: 663
Study 30972746 — intervention group
Group type: COMPARATOR
Intervention: etanercept 50 mg
Number of subjects: 663
Study 30294758 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 754
Study 30294758 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 754
Study 30294758 — intervention group
Group type: EXPERIMENTAL
Intervention: Including health spillover to one parent
Number of subjects: 754
Study 29911785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Cold Pack (ICT)
Number of subjects: 40
Study 29911785 — intervention group
Group type: COMPARATOR
Intervention: Modified Robert Jones Bandage (MRJ)
Number of subjects: 40
Study 25426978 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleanprep
Number of subjects: 173
Study 25426978 — intervention group
Group type: EXPERIMENTAL
Intervention: Picoprep
Number of subjects: 173
Study 24180588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level infrared diode laser (n = 54)
Number of subjects: 13
Study 24180588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride gel (n = 31)
Number of subjects: 13
Study 24180588 — intervention group
Group type: COMPARATOR
Intervention: Carbomer 940 gel (n = 32)
Number of subjects: 13
Study 21684606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 397
Study 21684606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 397
Study 21684606 — intervention group
Group type: COMPARATOR
Intervention: Sham/0.5 mg group
Number of subjects: 397
Study 20108856 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (5 sets of 6 repetitions of strenuous (80% 1‐RM) quadriceps and hamstring exercises)
Number of subjects: 14
Study 20108856 — intervention group
Group type: COMPARATOR
Intervention: Control group (performed only activities of daily living)
Number of subjects: 14
Study 16428554 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40
Study 16428554 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 12823158 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility testing group (38 patients)
Number of subjects: 77
Study 12823158 — intervention group
Group type: COMPARATOR
Intervention: No susceptibility testing group (39 patients)
Number of subjects: 77
Study 10667640 — intervention group
Group type: COMPARATOR
Intervention: MPFF 1000 mg/day for 6 weeks
Number of subjects: 30
Study 10667640 — intervention group
Group type: COMPARATOR
Intervention: MPFF 1000 mg/day for 2 months
Number of subjects: 30
Study 10667640 — intervention group
Group type: COMPARATOR
Intervention: MPFF 1000 mg once daily or bid for 2 months
Number of subjects: 30
Study 10667640 — intervention group
Group type: COMPARATOR
Intervention: MPFF 1000 mg/day
Number of subjects: 30
Study 10667640 — intervention group
Group type: COMPARATOR
Intervention: MPFF combined with classic treatment
Number of subjects: 30
Study 8859260 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (5 days per week for 5 weeks)
Number of subjects: 44
Study 8859260 — intervention group
Group type: COMPARATOR
Intervention: Control group (computer workshop participation)
Number of subjects: 44
Study 1298597 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized administration of gentamicin
Number of subjects: 106
Study 1298597 — intervention group
Group type: COMPARATOR
Intervention: Conventional administration of gentamicin
Number of subjects: 106
Study 6709175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall
Number of subjects: 0
Study 6709175 — intervention group
Group type: EXPERIMENTAL
Intervention: Yes/no recognition of words
Number of subjects: 0
Study 6709175 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in cued recall
Number of subjects: 0
Study 6709175 — intervention group
Group type: COMPARATOR
Intervention: Recognition memory
Number of subjects: 0
Study 30963321 — intervention group
Group type: EXPERIMENTAL
Intervention: imPACT intervention (motivational interviewing, care linkage coordination, text message medication reminders)
Number of subjects: 381
Study 30963321 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 381
Study 30963321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both imPACT and SC
Number of subjects: 381
Study 30108035 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERACT Quality Improvement Program
Number of subjects: 264
Study 30108035 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison NFs)
Number of subjects: 264
Study 27563205 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Number of subjects: 30
Study 27563205 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 30
Study 27563205 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish + 980 nm diode laser
Number of subjects: 30
Study 27563205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 24576865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min of treadmill interval exercise) before diving
Number of subjects: 19
Study 24576865 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control dive (CON)
Number of subjects: 19
Study 24576865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) dive
Number of subjects: 19
Study 22274735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24
Study 22274735 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 24
Study 19847430 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg/day
Number of subjects: 22
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication (ACM)
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic (AP) polypharmacy
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical AP drugs
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of depot and oral AP
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of APs
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of extrapyramidal side effects (EPS)
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of APs prescribed
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Study sites (HK and BJ)
Number of subjects: 505
Study 17397098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and atypical and oral AP
Number of subjects: 505
Study 16288613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine (group BM0.1)
Number of subjects: 119
Study 16288613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine (group BM0.2)
Number of subjects: 119
Study 16288613 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pethidine (group BPeth10)
Number of subjects: 119
Study 16288613 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine alone (group B)
Number of subjects: 119
Study 15259393 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dementia of the Alzheimer's type (DAT)
Number of subjects: 0
Study 15259393 — intervention group
Group type: COMPARATOR
Intervention: Controls (normal observers)
Number of subjects: 0
Study 15259393 — intervention group
Group type: COMPARATOR
Intervention: Normal observers (controls)
Number of subjects: 0
Study 10064007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 30
Study 10064007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7675571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mellow music (4:4 time)
Number of subjects: 20
Study 7675571 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenetic music (2:8 time)
Number of subjects: 20
Study 7675571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating scent
Number of subjects: 20
Study 7675571 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing scent
Number of subjects: 20
Study 7675571 — intervention group
Group type: COMPARATOR
Intervention: Control scent
Number of subjects: 20
Study 2368409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytron (electronic demand oxygen delivery system)
Number of subjects: 10
Study 2368409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymizer Pendant (reservoir cannula) at flow rates of 2, 3 and 41/min
Number of subjects: 10
Study 2368409 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow delivery
Number of subjects: 10
Study 497660 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneovenous (LeVeen) shunt
Number of subjects: 14
Study 497660 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 14
Study 30693627 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallowing training (EST)
Number of subjects: 24
Study 30693627 — intervention group
Group type: COMPARATOR
Intervention: Saliva swallowing (Control)
Number of subjects: 24
Study 28737608 — intervention group
Group type: COMPARATOR
Intervention: Biofinity single-vision contact lenses
Number of subjects: 443
Study 28737608 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal 'D' with a +1.50-D add power
Number of subjects: 443
Study 28737608 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal 'D' with a +2.50-D add power
Number of subjects: 443
Study 26391570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-Clopidogrel combined treatment (clopidogrel at an initial dose of 300 mg, then 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days)
Number of subjects: 129
Study 26391570 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone treatment (75 mg per day for 90 days)
Number of subjects: 129
Study 23129737 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa triptorelin plus norethisterone
Number of subjects: 129
Study 23129737 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone alone (control group)
Number of subjects: 129
Study 22108152 — intervention group
Group type: EXPERIMENTAL
Intervention: POM3 plus atorvastatin
Number of subjects: 237
Study 22108152 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atorvastatin
Number of subjects: 237
Study 19604318 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient appliance
Number of subjects: 80
Study 19604318 — intervention group
Group type: COMPARATOR
Intervention: Hard, palatal, non-occluding appliance (Control)
Number of subjects: 80
Study 19604318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 17197846 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE (family-centered behavioral preparation)
Number of subjects: 408
Study 15087796 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20
Study 15087796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11157586 — intervention group
Group type: COMPARATOR
Intervention: Short-term exercise therapy (3 months)
Number of subjects: 140
Study 11157586 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exercise therapy (18 months)
Number of subjects: 140
Study 9633195 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-aggressive period
Number of subjects: 0
Study 7908164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, 3 times/day)
Number of subjects: 19
Study 7908164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2709887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 64
Study 2709887 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Gentamicin
Number of subjects: 64
Study 1264935 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 5
Study 31159533 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational insertion technique
Number of subjects: 80
Study 31159533 — intervention group
Group type: COMPARATOR
Intervention: Classic midline insertion technique
Number of subjects: 80
Study 31159533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 29488482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursosan (UDCA) 15 mg/kg for 24 weeks
Number of subjects: 78
Study 29488482 — intervention group
Group type: COMPARATOR
Intervention: Phosphogliv
Number of subjects: 78
Study 25433982 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 4104